ArticleCancer discovery2018

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Sean D Reiff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.